Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

Launched by ABBVIE · Nov 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and satisfaction of a medication called ubrogepant for treating migraines in adults who have experienced multiple migraine attacks. Ubrogepant is already approved for treating migraines, and the trial will involve about 167 participants across several locations in Canada. To qualify for the study, participants must be at least 18 years old, have a history of migraines for at least a year, and have been experiencing three or more migraine attacks each month. They also need to be prescribed ubrogepant by their doctor before joining the study.

Participants in the trial can expect to take ubrogepant as directed by their physician and will be monitored for up to 12 weeks. There won’t be any extra burden, as they will attend regular visits at their usual hospital or clinic. It’s important to note that individuals who have previously used ubrogepant or have certain medical conditions may not be eligible for the study. Overall, this trial aims to help understand how well ubrogepant works in real-life situations and how satisfied patients are with this treatment for their migraines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants able to give voluntary informed consent before starting any study-related assessments or procedures (to be obtained/documented as per local regulations).
• • Adults (≥18 years of age) at time of informed consent.
• • Participants with at least 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (2018).
• • Participants with history of experiencing at least 3 migraine attacks per month with moderate to severe symptoms
• • Participants prescribed ubrogepant by investigator for the acute treatment of migraine according to local product label, independent of and prior to study participation
• • Participants willing and able to comply with the requirements of the study.
• • Participants with access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access.
• Exclusion Criteria:
• • Participants previously exposed to a ubrogepant or rimegepant as routine therapy or through a clinical trial.
• • Participants with history of known contraindications to ubrogepant as per local labeling.
• • Participants Pregnant or planning to be pregnant or of childbearing potential not using contraception
• • Participants enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies.
• • History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.